A Phase II Study of IMGN901 (Lorvotuzumab Mertansine; IND #: TBD, NSC: 783609) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma

Trial Profile

A Phase II Study of IMGN901 (Lorvotuzumab Mertansine; IND #: TBD, NSC: 783609) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Lorvotuzumab mertansine (Primary)
  • Indications Nerve sheath neoplasms; Neuroblastoma; Pulmonary blastoma; Rhabdomyosarcoma; Synovial sarcoma; Wilms' tumour
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results assessing the efficacy and tolerability of lorvotuzumab mertansine at the adult recommended phase 2 dose in children with relapsed tumors, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 20 Jan 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top